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Abstract Background Population-based studies investi-
gating indications for antidepressant prescribing mostly
rely on diagnoses from general practitioners. However,
diagnostic codes might be incomplete and drugs may be
prescribed ‘off-label’ for indications not investigated in
clinical trials. Objective We aimed to study indications for
antidepressant use based on self-report. Also, we studied
the presence of depressive symptoms associated with the
self-reported indications. Setting Our study population of
antidepressant users was selected based on interview data
between 1997 and 2013 from the prospective population-
based Rotterdam Study cohort (age [45 years). Method
Antidepressant use, self-reported indication for use, and
presence of depressive symptoms (Center for Epidemio-
logical Studies Depression Scale) were based on interview.
Self-reported indications were categorized by the
researchers into officially approved, clinically-accepted
and commonly mentioned off-label indications. Main out-
come measures A score of 16 and higher on the Center for
Epidemiological Studies Depression Scale was considered
as indicator for clinically-relevant depressive symptoms.
Results The majority of 914 antidepressant users reported
‘depression’ (52.4 %) as indication for treatment. Fur-
thermore, anxiety, stress and sleep disorders were reported
in selective serotonin reuptake inhibitor and other antide-
pressant users (ranging from 5.9 to 13.3 %). The indication
‘pain’ was commonly mentioned by tricyclic antidepres-
sant users (19.0 %). Indications were statistically signifi-
cantly associated with higher depressive symptom scores
when compared to non-users (n = 10,979). Conclusions
Depression was the main indication for antidepressant
treatment. However, our findings suggest that antidepres-
sants are also used for off-label indications, subthreshold
disorders and complex situations, which were all associated
with clinically-relevant depressive symptoms in the mid-
dle-aged and elderly population.
Keywords Antidepressive agents  Depression  Off-label
use  Self-report  The Netherlands
Impacts on practice
• Antidepressant use should not be used as a marker for
subclinical depressive symptoms in pharmacoepidemi-
ological research.
• Antidepressants are prescribed for subthreshold psy-
chiatric symptoms, complex, and possible off-label,
indications.
• Off-label antidepressant use seems common in the
elderly population and appropriateness of prescribing
should be further investigated.
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Introduction
Antidepressant use has increased substantially in the last
decades [1–3]. It has been suggested that antidepressants
are prescribed too easily [4, 5], or that antidepressants are
prescribed for a wider range of indications [2, 6]. Antide-
pressants are not only prescribed for depressive disorders,
but also for other approved (i.e. anxiety) and unapproved
indications, referred to as (clinically-accepted) off-label
indications, such as sleep disorders and neuropathic pain
[7]. A broadening in the number of indications for
antidepressant use might explain the rise in antidepressant
use over time [2, 6]. Pharmacoepidemiological studies that
investigated indications for antidepressant use often regis-
tered indications based on clinical diagnostic codes from
medical records [2, 7–10] or were based on diagnoses from
structured interviews with general practitioners (GPs)
[11, 12]. However, diagnostic codes might be incomplete if
not all indications were under investigation, subthreshold
psychiatric symptoms were not registered or because of
diagnostic uncertainty by the GP [2, 7–9].
Studies which investigate reasons for antidepressant
prescribing from a patients’ perspective give insight into
the original symptoms and primary condition as experi-
enced by the patient. Besides the traditional indications,
subthreshold disorders, physical comorbidities and life
events have been associated with use of antidepressants
[6, 13–15]. Further characterization of these individuals
and their, non-psychiatric, indications is needed.
Aim of the study
Our aim was to investigate indications for antidepressant
treatment based on patients’ self-reports in a population-
based cohort of middle-aged and elderly. Additionally, we
aimed to assess presence of depressive symptoms, as we
hypothesize that all indications might be accompanied by
comorbid depressive symptoms.
Ethics approval
The Rotterdam Study has been approved by the Medical
Ethics Committee of the Erasmus MC and by the Min-
istry of Health, Welfare and Sport of the Netherlands,
implementing the ‘‘Wet Bevolkingsonderzoek: ERGO
(Population Studies Act: Rotterdam Study)’’. All partic-
ipants provided informed consent to participate in the
study.
Method
Study setting
The study was conducted within the prospective popula-
tion-based Rotterdam Study. The Rotterdam Study was
initiated in 1990, and investigates the incidence of, and risk
factors for, several age-related diseases. Participants are
continuously followed for morbidity and mortality, and
follow-up visits are conducted every 4–5 years with an
extensive set of examinations (e.g. ECG, MRI-scan,
questionnaires). After extension over the years, the study
comprises a total of 14,926 participants. All participants
were aged 45 years or older at baseline. Detailed infor-
mation on design, objectives and methods of the Rotterdam
Study has been published elsewhere [16, 17].
Study population
From 1997 onwards, participants were interviewed every
4–5 years by research assistants about their current drug
use and indication for use (N = 11,860). We included
participants who reported antidepressant use at one of the
interview rounds (between 1997 and 2013). Home inter-
views of other participants, with complete interview data,
were included as reference population of non-users.
Home interviews
Participants were asked to present all their drug containers
during the home interview. Drug names, dosages, and
regimen were registered by research assistants. Antide-
pressants were selected, based on their Anatomical Ther-
apeutic Chemical (ATC) code (ATC code = N06A), and
categorized into tricyclic antidepressants (TCAs, ATC-
code = N06AA), selective serotonin reuptake inhibitors
(SSRIs, ATC-code = N06AB) and other antidepressants
(ATC-code = N06AF/AG/AX). St John’s wort was not
taken into account. Moreover, participants were asked for
which indications the specific drugs were taken. The
symptoms or disorders mentioned by the participant were
registered as ‘free text’, without interpretation or adjust-
ment by the research assistants. Two researchers (NA and
RN) independently categorized the complete list of symp-
toms and disorders into eight groups. Discrepancies were
discussed to reach final consensus. The categories would
represent disorders and related symptoms, and were based
on officially approved and clinically-accepted indications
extended with common off-label indications mentioned in
previous literature (Table 1) [7, 9, 18].
As part of the home interview, presence of depressive
symptoms in the past week before interview were screened
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for with a Dutch version of the Center for Epidemiological
Studies Depression Scale (CES-D) [19]. A score of 16 and
higher was considered as an indicator for clinically-rele-
vant depressive symptoms [20].
Statistical analyses
We included the first eligible interview of participants.
Self-reported indications were presented for the total group
of antidepressant users and stratified by antidepressant
class (TCA, SSRI, other). Participants could report multi-
ple antidepressants and indications in an interview. In a
subsample analysis, we excluded participants without
information regarding cognitive functioning or with
possible cognitive impairment (Mini-Mental State Exami-
nation score B23 [21]), as cognitive impairment may affect
the validity of self-reported data. Also, indications for
treatment were stratified by age (B65,[65 years) and sex.
In an additional analysis, we included follow-up interview
rounds to map whether participants reported antidepressant
use at multiple rounds and whether indications for treat-
ment were consistent over the rounds.
The median depression score and the percentage of par-
ticipants with clinically relevant depressive symptoms were
presented for all indications of treatment and for non-users.
Median scores and percentages for every indication category
were compared to non-users or compared to the group with
indication ‘depression’ with a Mann–Whitney U, or Pearson
Table 1 Overview of indications and their corresponding self-reported symptoms, and the registered approved or clinically-accepted
antidepressants
Category Reported symptoms Approved antidepressants Clinically-accepted
antidepressants a
Depression Depression, anti-depressant, feeling down, discouraged All
Anxiety Anxiety, panic, hyperventilation Clomipramine, venlafaxine,
duloxetine and SSRIsb
Imipramine
Stress Stress, burn-out, restlessness, soothing
Sleep disorders Insomnia, to fall asleep, sleep
Headache/migraine Headache, migraine
Pain Pain, nerve pain, hernia, fibromyalgia, shingles Duloxetine Amitriptyline
Other indications Parkinson’s disease, menopause, tingling legs, general
mental problems
Unknown No answer, unknown
SSRIs selective serotonin reuptake inhibitors
a Clinically-accepted antidepressants are mentioned in the national therapeutic monitoring system
b Some SSRIs are only registered for specific anxiety disorders, however we consider all SSRIs registered as we cannot distinguish these specific
anxiety disorders
Table 2 Self-reported
indications for all antidepressant
users and stratified by type of
antidepressant
Total TCA SSRI Other
N = 914 N = 270 N = 498 N = 153
N (%) N (%) N (%) N (%)
Reported indication for usea
Depression 479 (52.4) 80 (29.6) 307 (61.6) 92 (60.1)
Anxiety 80 (8.8) 6 (2.2) 65 (13.1) 9 (5.9)
Stress 119 (13.0) 39 (14.4) 66 (13.3) 14 (9.2)
Sleep disorders 45 (4.9) 28 (10.4) 6 (1.2) 11 (7.2)
Headache/migraine 10 (1.1) 9 (3.3) 1 (0.2) 0 (0.0)
Pain 54 (5.9) 51 (18.9) 1 (0.2) 2 (1.3)
Other 48 (5.3) 19 (7.0) 18 (3.6) 11 (7.2)
Unknown 123 (13.5) 46 (17.0) 57 (11.4) 20 (13.1)
Number of separate antidepressants and indications do not add up to the total number of unique participants
(n = 914), as participants could report multiple antidepressants and indications at one interview round
TCA tricyclic antidepressants, SSRIs selective serotonin reuptake inhibitors
a Reported indications for antidepressant use represent disorders and related symptoms. See Table 1
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Chi square test. For these analyses regarding the depression
score, we categorized participants who reported multiple
antidepressants and indications in an interview as a separate
category. A p value below 0.05 was considered statistically
significant and IBM SPSS Statistics (version 21.0, IBM
Corp., Somers, NY, USA) was used for analyses.
Results
Of the 11,860 participants, a total of 914 (7.7 %) individ-
uals reported to be current antidepressant user at one or
multiple interview rounds. At the first eligible interview
round, the mean age of the antidepressant users was
67.3 years (SD 10.7), 72.3 % were women, and most
participants were prescribed an SSRI (54.5 %).
Depression was most commonly reported as indication
for treatment in the antidepressant users (52.4 %, Table 2).
SSRIs and other antidepressants were most often used for
depression, anxiety and stress symptoms, although other
antidepressants were also prescribed for sleep disorders and
other indications. Of the TCA users, only 29.6 % reported
depression as an indication, while stress (14.4 %), sleep
disorders (10.4 %) and pain (18.9 %) were also frequently
reported. In total, antidepressant use was in 60.1 % of the
reported indications for approved indications, 5.1 % for
clinically-accepted indications (i.e. mostly amitriptyline for
pain) and 36.6 % would be considered off-label. Other
reported indications were menopausal complaints, tingling
or restless legs, Parkinson’s disease and general mental
health problems (Table 1). Percentages did not materially
change when we excluded participants with possible cog-
nitive impairment (subsample n = 717, results not shown).
Moreover, stratification by age (cut-off B65, [65 years)
showed higher percentages of depression (61.0 vs. 45.0 %)
and anxiety-related (14.4 vs. 3.9 %) indications in the
younger population than in the older population, while the
older population had a higher percentage of stress related
(9.0 vs. 16.5 %) and unknown indications (5.0 vs. 20.8 %).
Stratification by gender showed comparable indications for
treatment for men and women (results not shown). A total of
358 participants reported antidepressant use at two mea-
surement rounds. Self-reported indications for depression
and anxiety remained relatively stable over time with
78.4 % reporting depression or anxiety at both interview
rounds. In participants who initially reported other or
unknown indications, 40.7 % did report depression or
anxiety at follow-up measurement round.
All indications, except headache, were associated with a
significantly higher percentage of participants with clini-
cally-relevant depressive symptoms or a higher median
CES-D score than the non-users (8.1 %, median 2.0,
interquartile range 0.0–7.0). Of the antidepressant users
with the self-reported indication depression, 36.9 % also
had clinically-relevant depressive symptoms as measured
by questionnaire. Nonetheless, of the users who exclusively
reported another indication for use, 23.4 % had clinically-
relevant depressive symptoms ranging from 15.9 to 29.2 %
over the different indication categories (Table 3). How-
ever, the percentage with clinically-depressive symptoms
was significantly lower in participants who exclusively
reported another indication for use, when compared to the
indication ‘depression’. An exceptional category was the
group with multiple indications or antidepressants at an
interview round. These participants had a median depres-
sion score of 12.5 (interquartile range 4.5–20.0), with a
total of 42.9 % of participants with clinically-relevant
depressive symptoms, which was significantly higher when
compared to the non-users group, but similar to the users
with the self-reported indication depression (Table 3).
Discussion
In line with other studies, we observed in our study pop-
ulation of older adults that depression was the most fre-
quently reported indication for antidepressant use
[2, 7, 10, 11]. Of those who reported depression as indi-
cation for treatment, around 40 % actually reported clini-
cally-relevant depressive symptoms based on assessment
with the CES-D. Possibly, antidepressants were prescribed
for mild depressive symptoms, or participants were on
maintenance treatment after successful antidepressant
treatment [13, 22].
As hypothesized, more than 20 % of users also reported
clinically-relevant depressive symptoms for indications
other than depression, and had a higher depression score
when compared to non-users. Two possible explanations
will be discussed. First, we were able to capture mild or
isolated symptoms, such as restlessness and fatigue, which
do not conform to the diagnostic label depression accord-
ing to the DSM-IV criteria. Yet, these are symptoms which
could be part of a possible depression. Second, symptoms
such as depression, social problems, distress and physical
symptoms are highly correlated and often occur concomi-
tantly. Depression might be a secondary indication next to
the reported primary condition [11, 23–25]. 40 % of the
participants who used antidepressants during two inter-
views reported anxiety or depression at follow-up, while
they reported another indication at baseline. The statement
that the profile of antidepressant use is complex is further
supported by the fact that participants with multiple indi-
cations also reported a high level of depressive symptoms,
even similar to the group who reported depression as
indication for treatment. Nevertheless, antidepressant use
cannot be used as a marker for subclinical depressive
1314 Int J Clin Pharm (2016) 38:1311–1317
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symptoms. In most users which exclusively reported
another indication, the overall percentage of depressive
symptoms was significantly lower when compared to those
who reported depression as indication for treatment.
In contrast, almost 80 % of users with an indication
other than depression did not report concurrent depressive
symptoms. In this case, the reported (off-label) indications
such as anxiety, pain, stress or sleeping disorders were the
main reason for prescribing according to the patient. For
example, we observed that almost one fifth of all TCA
prescriptions were reported as being used for pain. This
proportion was higher than in previous studies [7, 10],
which might be due to the high average age of our popu-
lation because pain is highly prevalent in the elderly [26].
The off-label indication ‘stress’ was also frequently men-
tioned in our study. This might relate to participants who
experience psychosocial problems and distress, without
clinical depressive symptoms which justified antidepres-
sant prescribing. Previous studies already reported that,
besides the traditional indications, combinations of other
mental complaints, multi-morbidity, psychosocial prob-
lems and social distress are also important reasons to pre-
scribe antidepressants [5, 6, 13–15]. This may be
particularly important in our elderly population as elderly
experience more life events, physical impairment and
general health complaints. This is confirmed after our
stratification on age as the percentage with stress related
indications is even higher in the elderly population.
Although prescriptions for these indications seem off-label,
no conclusions can be drawn regarding the appropriateness
of the antidepressant prescribing in our study. Information
from detailed individual medical records would be
required.
Previous studies already reported that antidepressants
are being prescribed for other, possible off-label, indica-
tions, however these results are most often based on clin-
ical diagnostic codes [2, 7–10], which does not provide a
complete representation [2, 7–9]. Other more qualitative
studies provide a more complete representation of the
complex and different combinations of indications, but
they were always influenced by a physician’s judgement or
still focused on psychiatric disorders. We provide a unique
insight from a patients’ perspective into the original
symptoms and primary condition as experienced by the
patient. We report a complete overview of all possible
indications with antidepressant use in a daily practice
setting.
Other strengths of our study are the population-based
setting and the availability of interview data from partici-
pants on antidepressant use, indication for use and
depression score at the same point in time. However, some
limitations should be addressed. First, in a prospective
Table 3 Self-reported indications for antidepressant use and presence of depressive symptoms
N Median CES-D score
Median (IQR)
Presence of depressive
symptomsd
N (%)
Non–use 10,797 2.0 (0.0–7.0) 877 (8.1)
Reported indication for usea
Depression 436 11.0 (3.0–20.8)b 161 (36.9)b
Single indications except depression 410 8.0 (3.0–15.0)b,c 96 (23.4)b,c
Anxiety 59 5.0 (2.0–13.0)b,c 10 (16.9)b,c
Stress 105 9.5 (3.0–16.5)b 27 (24.7)b,c
Sleep disorders 33 7.0 (3.0–15.5)b 8 (24.2)b
Headache/migraine 8 1.0 (0.0–14.3) 2 (25.0)
Pain 48 5.0 (1.0–13.8)b,c 9 (18.8)b,c
Other 44 6.5 (2.3–13.0)b,c 7 (15.9)c
Unknown 113 9.0 (4.5–16.9)b 33 (29.2)b
Multiple indications 42 12.5 (4.5–20.0)b 18 (42.9)b
Complete caseset analysis. St John’s wort was not taken into account as antidepressant and excluded from the non-use group. N does not
correspond with total N in Table 2: CES-D data was missing for 26 antidepressant users, and participants with multiple indications or
antidepressants were categorized in a separate group (‘multiple’), and were only taken into account once
CES-DCenter for Epidemiological Studies Depression Score, IQR interquartile range
a Reported indications for antidepressant use represent disorders and related symptoms. See Table 1
b Significantly different from non-use (p\ 0.05)
c Significantly different from the indication ‘depression’ (p\ 0.05)
d Presence of depressive symptoms is based on a Center for Epidemiological Studies Depression Score of 16 or higher
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cohort study such as the Rotterdam Study a healthy vol-
unteer bias may be considered as a sort of selection bias
[27]. Second, indications based on self-report might be
biased as they relate to individual cognitive and linguistic
abilities. However, results did not materially differ after
exclusion of participants with possible mild cognitive
impairment. Third, there may be a discrepancy between a
physicians intended indication for use and the patients
perception on it. Unfortunately, we did not have the
physicians diagnoses to compare with the self-reported
indication for use. Fourth, reported symptoms were man-
ually categorized by two independent researchers in dif-
ferent indication groups. These categories might not be
mutually exclusive from each other as symptoms often co-
exist and are not always distinctive for one specific indi-
cation. Fifth, the majority of our analyses were based on
cross-sectional data and do not capture changes in symp-
toms over time.
Conclusion
Our results suggest that apart from the product-labelled
indications, antidepressant use is common for self-reported
off-label indications, subthreshold disorders and distress in
the middle-aged and elderly population. Clinically-relevant
depressive symptoms were observed for indications other
than depression, which suggests that there is a high cor-
relation between physical problems, psychological distress
and depression. Thus, according to antidepressants users
they not only use antidepressants to treat the traditional
indications of depression and anxiety. Further research is
needed to study whether antidepressant use is justified in
these cases. The balance between possible effectiveness
and risk of adverse drug reactions should be weighted
carefully, especially in the elderly population which are at
high risk of adverse drug reactions and drug-drug
interactions.
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